Devendra Hiwase

3.4k citations

134 papers · 2.5k · 2 hit papers · h-index 29

Impact in

Hematology top 0.5%
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Hematopoietic Stem Cell Transplantation
- Multiple Myeloma Research and Treatments
- Blood groups and transfusion
Oncology top 10%
- Drug Transport and Resistance Mechanisms

Papers in

Hematology 114
- Acute Myeloid Leukemia Research 69
- Chronic Myeloid Leukemia Treatments 27
- Hematopoietic Stem Cell Transplantation 11
- Multiple Myeloma Research and Treatments 5
- Blood groups and transfusion 3
Oncology 9
- Drug Transport and Resistance Mechanisms 6

Co-authors: Timothy P. Hughes (28 shared papers)Deborah L. White (20 shared papers)Christopher Norman Hahn (12 shared papers)Sharad Kumar (8 shared papers)David M. Ross (19 shared papers)Hamish S. Scott (10 shared papers)Michael Bailey (3 shared papers)Verity A Saunders (8 shared papers)
Journals: Blood (39 papers)Blood Advances (12 papers)Leukemia (11 papers)American Journal of Hematology (7 papers)Transplantation and Cellular Therapy (6 papers)
Partner nations: Australia United States United Kingdom

In The Last Decade

Devendra Hiwase

128 papers receiving 2.4k citations

Devendra Hiwase's Hit Papers

align trajectories log scale

Magrolimab plus azacitidine vs physician’s choice for untreated TP53 -mutated acute myeloid leukemia: the ENHANCE-2 study 2025 · 39 citations

What are hit papers?

Paper score: A paper's citations measured against the top-1% bar of its own field and year: the square root of citations ÷ bar, so 1 means right at the bar and 2 means four times its citations. The bar blends the citation counts that enter the top 1% of the paper's subfields in its year (weighted 89.5%), of those subfields over all years (0.5%) and of its year across all fields (10%); a subfield and year with fewer than 400 papers takes its year's bar. Papers from 2026 are not scored yet: in an unfinished year, when a paper appeared matters more than how it is cited.

Hit paper: A paper cited at least 1.5× the top-1% bar of its field and year: a paper score of at least √1.5.

2025 Blood
2023 Blood Advances

Peers

Countries citing papers authored by Devendra Hiwase

Since Specialization

Citations

This map shows the geographic impact of Devendra Hiwase's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Devendra Hiwase with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Devendra Hiwase more than expected).

Fields of papers citing papers by Devendra Hiwase

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Devendra Hiwase. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Devendra Hiwase. The network helps show where Devendra Hiwase may publish in the future.

Co-authors

The 25 scholars most cited alongside Devendra Hiwase, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Devendra Hiwase Line = papers co-authored together Devendra Hiwase links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 134 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Dasatinib Cellular Uptake and Efflux in Chronic Myeloid Leukemia Cells: Therapeutic Implications Clinical Cancer Research ·Devendra Hiwase, Verity A Saunders, Duncan R. Hewett, Amity Frede, Stephanie Zrim, Phuong Dang, Laura N Eadie, L.B. To	2008	164
2	RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML Blood Advances ·Anna L Brown, Peer Arts, Catherine Carmichael, Milena Babic, Julia Dobbins, Chan‐Eng Chong, ANDREAS W. SCHREIBER, Jinghua Feng	2020	114
3	Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML Blood Advances ·Stéphane de Botton, Pierre Fenaux, Karen W L Yee, Christian Récher, Andrew H. Wei, Pau Montesinos, David Christopher Taussig, Arnaud Pigneux Hit paper breakdown →	2023	102
4	TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets Blood ·David T. O. Yeung, Michael Philip Osborn, Deborah L. White, Susan Branford, Jodi A. Braley, Alan Herschtal, Samar Issa, Devendra Hiwase	2014	93
5	Monoclonal antibody targeting of IL-3 receptor α with CSL362 effectively depletes CML progenitor and stem cells Blood ·Eva Nievergall, Hayley S. Ramshaw, Agnes S. M. Yong, Mark Biondo, Samantha J. Busfield, Gino Vairo, Angel Francisco Lopez, Timothy P. Hughes	2013	86
6	Higher Infused Lymphocyte Dose Predicts Higher Lymphocyte Recovery, Which in Turn, Predicts Superior Overall Survival following Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma Transplantation and Cellular Therapy ·Devendra Hiwase, Smita D. Hiwase, Michael Bailey, Geraldine M. Bollard, Anthony P. Schwarer	2007	76
7	Myeloid neoplasms with germline DDX41 mutation International Journal of Hematology ·Jesse Cheah, Christopher Norman Hahn, Devendra Hiwase, Hamish S. Scott, Anna L Brown	2017	74
8	Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia Blood ·Naranie Shanmuganathan, Ilaria Stefania Pagani, David M. Ross, Sa-Hee Park, Agnes S. M. Yong, Jodi A. Braley, Haley K. Altamura, Devendra Hiwase	2020	64
9	Loss of caspase-2 augments lymphomagenesis and enhances genomic instability in Atm -deficient mice Proceedings of the National Academy of Sciences ·Joseph Puccini, Sonia Shalini, Anne Kathrin Voss, Magtouf Hnaidi Gatei, Claire H. Wilson, Devendra Hiwase, Martin Francis Lavin, Loretta Dorstyn	2013	58
10	Dysregulated Lipid Synthesis by Oncogenic IDH1 Mutation Is a Targetable Synthetic Lethal Vulnerability Cancer Discovery ·DANIEL W. THOMAS, Manhong Wu, Yusuke Nakauchi, Ming Zheng, Chloe A. L. Thompson-Peach, Kelly SY Lim, Niklas Landberg, Thomas Köhnke	2022	51
11	The mutational burden of therapy-related myeloid neoplasms is similar to primary myelodysplastic syndrome but has a distinctive distribution Leukemia ·Deepak Singhal, Li Yan A. Wee, Monika Kutyna, Rakchha Chhetri, Joel M. Geoghegan, ANDREAS W. SCHREIBER, Jinghua Feng, Paul Po-Shen Wang	2019	50
12	Intermediate-dose CY and G-CSF more efficiently mobilize adequate numbers of PBSC for tandem autologous PBSC transplantation compared with low-dose CY in patients with multiple myeloma Cytotherapy ·Devendra Hiwase, Geraldine M. Bollard, Smita D. Hiwase, Michael Bailey, J. Muirhead, ANTHONY P. SCHWARER	2007	47
13	Red cell alloimmunization is associated with development of autoantibodies and increased red cell transfusion requirements in myelodysplastic syndrome Haematologica ·Deepak Singhal, Monika Kutyna, Rakchha Chhetri, Li Yan A. Wee, Sophia Hague, Lakshmi Nath, Shriram Vaidia Nath, R. K. Sinha	2017	47
14	TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy Leukemia ·Eva Nievergall, John Reynolds, Chung Hoow Kok, Dale B. Watkins, Mark Biondo, Samantha J. Busfield, Gino Vairo, Kathryn A. Fuller	2016	44
15	Targeted gene panels identify a high frequency of pathogenic germline variants in patients diagnosed with a hematological malignancy and at least one other independent cancer Leukemia ·Deepak Singhal, Christopher Norman Hahn, Simone K. Feurstein, Li Yan A. Wee, Luke Moma, Monika Kutyna, Rakchha Chhetri, Leila Eshraghi	2021	44
16	Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors Leukemia ·Devendra Hiwase, Deborah L. White, Jason A. Powell, Verity A Saunders, Steph Zrim, Amity Frede, Mark A. Guthridge, Angel Francisco Lopez	2010	40
17	Splice factor mutations and alternative splicing as drivers of hematopoietic malignancy Immunological Reviews ·Christopher Norman Hahn, Parvathy Venugopal, Hamish S. Scott, Devendra Hiwase	2014	40
18	Ndfip1-deficient mice have impaired DMT1 regulation and iron homeostasis Blood ·Natalie J. Foot, Yew Ann Leong, Loretta Dorstyn, Hazel E. Dalton, Kristen Ho, Lin Zhao, Michael D. Garrick, Baoli Yang	2010	39
19	Magrolimab plus azacitidine vs physician’s choice for untreated TP53 -mutated acute myeloid leukemia: the ENHANCE-2 study Blood ·Joshua F. Zeidner, David Andrew Sallman, Christian Récher, Naval Guastad Daver, Anskar YH Leung, Devendra Hiwase, Thomas Pabst, Pau Montesinos Hit paper breakdown →	2025	39
20	Allogeneic hematopoietic stem cell transplant outcomes in adults with inherited myeloid malignancies Blood Advances ·Caner Saygin, Gregory W. Roloff, Christopher Norman Hahn, Rakchha Chhetri, Saar I. Gill, Hany Elmariah, Chetasi Talati, Emma Nunley	2022	38

About Devendra Hiwase

Devendra Hiwase is a scholar working on Hematology, Oncology, Genetics, Genetics and Geriatrics and Gerontology, having authored 134 papers that have together received 2.5k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (69 papers), Chronic Myeloid Leukemia Treatments (27 papers), Hematopoietic Stem Cell Transplantation (11 papers), Blood disorders and treatments (6 papers), Drug Transport and Resistance Mechanisms (6 papers), Multiple Myeloma Research and Treatments (5 papers), Frailty in Older Adults (3 papers) and Blood groups and transfusion (3 papers). The work is most often cited by research in Hematology (1.8k citations), Oncology (204 citations), Genetics (77 citations), Geriatrics and Gerontology (25 citations) and Biochemistry (41 citations). Devendra Hiwase has collaborated with scholars based in Australia, United States and United Kingdom. Frequent co-authors include Timothy P. Hughes, Deborah L. White, Christopher Norman Hahn, Sharad Kumar, David M. Ross, Hamish S. Scott, Michael Bailey, Verity A Saunders, David T. O. Yeung and Deepak Singhal. Their work appears in journals such as Blood, Blood Advances, Leukemia, American Journal of Hematology and Transplantation and Cellular Therapy.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Devendra Hiwase

Impact in

Papers in i

In The Last Decade

Devendra Hiwase

Devendra Hiwase's Hit Papers

Peers

Countries citing papers authored by Devendra Hiwase

Fields of papers citing papers by Devendra Hiwase

All Works

About Devendra Hiwase

Explore authors with similar magnitude of impact

Papers in